

Granules Pharma launches generic Methylergonovine tablets

31 May 2018 | News

Methylergonovine is a semi-synthetic ergot alkaloid used for the prevention and control of postpartum haemorrhage.



Granules Pharmaceuticals, Inc., the wholly owned subsidiary of Granules India Ltd., has launched the generic version of Methylergonovine Maleate Tablets, USP, 0.2mg, the generic equivalent to Methergine in partnership with West-Ward Pharmaceuticals Corp. (West-Ward), a wholly-owned subsidiary of Hikma Pharmaceuticals PLC (Hikma).

Methylergonovine is a semi-synthetic ergot alkaloid used for the prevention and control of postpartum haemorrhage.

“This is the first product we have commercialized from our R&D and manufacturing facility in Virginia and we are happy to have collaborated with Hikma . Apart from the fact that Hikma has a proven history of being a responsible player in the market, we look at this launch as the inception towards building a strategic relationship. The launch of generic Methergine tablets plays into our strategy of identifying patient needs and catering to them with economical alternatives.” said Ms. Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals, Inc.

Brian Hoffmann, President of West-Ward, said, “We are very pleased to be entering into a partnership with Granules Pharmaceuticals, Inc., adding this important oxytocic agent to our product portfolio in the US. This partnership demonstrates our focus on improving patient’s access to high-quality, affordable medicines.”